Headlines about Intrexon Corporation (NYSE:XON) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intrexon Corporation earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.2967823100073 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the media stories that may have effected Accern’s analysis:

A number of equities analysts have issued reports on the stock. BidaskClub cut shares of Intrexon Corporation from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 22nd. Northland Securities set a $30.00 target price on shares of Intrexon Corporation and gave the company a “buy” rating in a research note on Monday, August 7th. Finally, Zacks Investment Research lowered shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Intrexon Corporation currently has an average rating of “Hold” and a consensus price target of $41.00.

Shares of Intrexon Corporation (XON) opened at 19.82 on Thursday. The company’s market cap is $2.39 billion. The company’s 50-day moving average is $18.97 and its 200 day moving average is $21.11. Intrexon Corporation has a 1-year low of $17.03 and a 1-year high of $32.90.

Intrexon Corporation (NYSE:XON) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. Intrexon Corporation had a negative net margin of 60.63% and a negative return on equity of 19.08%. The company had revenue of $54.40 million for the quarter, compared to analysts’ expectations of $57.17 million. During the same period in the prior year, the business earned ($0.42) EPS. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. Equities analysts anticipate that Intrexon Corporation will post ($0.87) EPS for the current year.

In other news, CEO Randal J. Kirk purchased 132,625 shares of the stock in a transaction dated Friday, August 11th. The shares were acquired at an average cost of $18.85 per share, for a total transaction of $2,499,981.25. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Robert B. Shapiro purchased 2,850 shares of the stock in a transaction dated Tuesday, August 22nd. The stock was purchased at an average price of $17.50 per share, for a total transaction of $49,875.00. Following the completion of the acquisition, the director now directly owns 43,157 shares in the company, valued at approximately $755,247.50. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 144,569 shares of company stock worth $2,719,429. 55.10% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Marea Informative and is owned by of Marea Informative. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at http://www.mareainformativa.com/intrexon-corporation-xon-earns-news-impact-rating-of-0-16/116978/.

Intrexon Corporation Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Insider Buying and Selling by Quarter for Intrexon Corporation (NYSE:XON)

Receive News & Stock Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related stocks with our FREE daily email newsletter.